In vitro test results obtained in 24 hours versus 7 days in animal
MONTREAL, Aug. 14 /CNW Telbec/ - (TSX.V: BUG). Biophage Pharma Inc.
(Biophage) is very pleased to announce that its PDS(R)-16 Biosensor can
determine the toxic effects (predictive toxicity) of Cyanobacteria on living
cells. Cyanotoxins provided by U.S. EPA (Environmental Protection Agency) were
used to generate data demonstrating that this biosensor can detect toxins
produced by Cyanobacteria in a vastly improved time frame.
Cyanobacterial toxins are a major determinant of health effects
associated with ingestion of water contaminated by Cyanobacteria. Despite the
growing awareness of this important issue, rapid and precise methodologies
that can detect and quantify the effects of these toxins on living cells are
still a major challenge. Actually, toxicity methods rely essentially on animal
bioassay and take about 7 days to be completed. Our technology is an automated
cell growth assay that is simple, easy to use and label-free allowing on-line
monitoring of toxicity within 24 hours.
"At Biophage we are extremely pleased to announce that our recently
launched PDS(R) -16 Biosensor system can be used for the detection of
Cyanotoxins in fresh water. These results open completely new markets for our
biosensors in assessing health risks associated with exposure to Cyanotoxins.
Currently, the global market for water safety monitoring and purification
represents a multi-billion dollar opportunity" stated Dr. Rosemonde
Mandeville, President and CEO of Biophage Pharma Inc. "Cyanobacteria
contamination of fresh water and marine environments worldwide indicate
potential problems for widespread human and animal health risks. We believe
that our PDS(R)-16 Biosensor could provide faster exposure assessment and
long-term monitoring of our rivers and lakes," concluded Dr Mandeville.
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian
biotechnology company focused on the development of innovative phage-based
products and technologies for the detection, prevention and control of
bacterial infections. Founded in 1995, Biophage operates three divisions:
(1) The Biosensors division for the development and commercialization of
Biosensors, more particularly the PDS(R) Biosensor; (2) The phage therapy
division for the prevention and control of bacterial contaminations in the
medical, veterinary and environment fields; (3) The Immunotox Labs division,
which provides services in Immunogenicity and Immunotoxicity, Beryllium
sensitivity testing and MELISA(R) testing for the detection of sensitization
to more than 200 different allergens including metals, penicillin, gluten,
pollens and more recently Lyme disease (Boreliosis). (www.biophagepharma.net;
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and CEO, (514) 496-1488,
email@example.com; Louis Guindon, Chief Financial
officer, (514) 496-3230, firstname.lastname@example.org